Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
PROUD Study - Preventing Opioid Use Disorders
- Conditions
- Interventions
- Behavioral: Guided mindfulness exercisesOther: Self-administered aromatherapyDrug: Baby aspirinDrug: Tylenol/AcetaminophenDrug: PregabalinDrug: PrednisoneDrug: MeloxicamDrug: PrilosecDrug: TramadolDrug: VoltarenDrug: ZofranDrug: PepcidDrug: ReglanDrug: VersedDrug: LidocaineDrug: PropofolDrug: AncefDrug: Tranexamic Acid (TXA)Drug: DecadronDrug: Bupivacaine hydrochlorideDrug: Toradol
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Emory University
- Target Recruit Count
- 57
- Registration Number
- NCT04766996
- Locations
- 🇺🇸
Emory University Orthopaedic and Spine Hospital, Atlanta, Georgia, United States
Haloperidol for the Treatment of Nausea and Vomiting in the ED
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Western Michigan University School of Medicine
- Target Recruit Count
- 60
- Registration Number
- NCT04764344
- Locations
- 🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States
Prevention of Post-Operative Shivering
- Conditions
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 120
- Registration Number
- NCT04682743
- Locations
- 🇪🇬
Cairo university, Cairo, Egypt
The Effect of Intravenous Granisetron and Ondansetron in Patients Undergoing Cesarean Section
- Conditions
- Interventions
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Ataturk University
- Target Recruit Count
- 120
- Registration Number
- NCT04613726
- Locations
- 🇹🇷
Mehmet AKSOY, Erzurum, string:Turkey, Turkey
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 89
- Registration Number
- NCT04557189
- Locations
- 🇺🇸
Stony Brook Medicine - Hospital, Stony Brook, New York, United States
🇺🇸Phoenix Clinical Research, Tamarac, Florida, United States
🇺🇸Helen Keller Hospital, Sheffield, Alabama, United States
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT04503668
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Ondansetron Effect on Pain Relief After Laparoscopic Cholecystectomy
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2021-01-12
- Target Recruit Count
- 50
- Registration Number
- NCT04468685
- Locations
- 🇪🇬
The National Hepatology and Tropical Research medicine institute, Cairo, Egypt
Usage of Multiple Drugs in Treatment of Postoperative Vomiting After Laparoscopic Appendectomy
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- King Abdul Aziz Specialist Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT04403191
- Locations
- 🇸🇦
King abd el Aziz specialist hospital, Taif, Saudi Arabia
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT04209595
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 52
- Registration Number
- NCT04169828
- Locations
- 🇨🇦
University of Calgary / Alberta Children's Hospital, Calgary, Alberta, Canada
🇨🇦BC Children's Hospital, Vancouver, British Columbia, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.